Literature DB >> 17229751

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

F Paul, J Dörr, J Würfel, H-P Vogel, F Zipp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17229751      PMCID： PMC2077678          DOI： 10.1136/jnnp.2006.091033

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  18 in total

1.  Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?

Authors:  N G Bellenger; M I Burgess; S G Ray; A Lahiri; A J Coats; J G Cleland; D J Pennell
Journal:  Eur Heart J       Date:  2000-08       Impact factor: 29.983

2.  Echocardiography in serial evaluation of left ventricular systolic and diastolic function: importance of image acquisition, quantitation, and physiologic variability in clinical and investigational applications.

Authors:  H F Kuecherer; L L Kee; G Modin; M D Cheitlin; N B Schiller
Journal:  J Am Soc Echocardiogr       Date:  1991 May-Jun       Impact factor: 5.251

Review 3.  Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods.

Authors:  James H McGowan; John G F Cleland
Journal:  Am Heart J       Date:  2003-09       Impact factor: 4.749

4.  Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

Authors:  Jagannadha R Avasarala; Anne H Cross; David B Clifford; Barry A Singer; Barry A Siegel; Elliot E Abbey
Journal:  Mult Scler       Date:  2003-02       Impact factor: 6.312

Review 5.  Current perspectives in diastolic dysfunction and diastolic heart failure.

Authors:  Adelino F Leite-Moreira
Journal:  Heart       Date:  2006-05       Impact factor: 5.994

6.  Adriamycin cardiotoxicity: a survey of 1273 patients.

Authors:  C Praga; G Beretta; P L Vigo; G R Lenaz; C Pollini; G Bonadonna; R Canetta; R Castellani; E Villa; C G Gallagher; H von Melchner; M Hayat; P Ribaud; G De Wasch; W Mattsson; R Heinz; R Waldner; K Kolaric; R Buehner; W Ten Bokkel-Huyninck; N I Perevodchikova; L A Manziuk; H J Senn; A C Mayr
Journal:  Cancer Treat Rep       Date:  1979-05

Review 7.  Mitoxantrone in progressive multiple sclerosis: when and how to treat?

Authors:  R E Gonsette
Journal:  J Neurol Sci       Date:  2003-02-15       Impact factor: 3.181

8.  Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics.

Authors:  B Marchandise; E Schroeder; A Bosly; C Doyen; P Weynants; R Kremer; H Pouleur
Journal:  Am Heart J       Date:  1989-07       Impact factor: 4.749

9.  Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.

Authors:  S A Mortensen; H S Olsen; U Baandrup
Journal:  Br Heart J       Date:  1986-03

10.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321
View more
  21 in total

1.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

Review 2.  Treatment of multiple sclerosis: role of natalizumab.

Authors:  Giancarlo Comi
Journal:  Neurol Sci       Date:  2009-10       Impact factor: 3.307

Review 3.  Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  James J Marriott; Janis M Miyasaki; Gary Gronseth; Paul W O'Connor
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 4.  [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors:  L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

5.  Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

Authors:  E Kingwell; M Koch; B Leung; S Isserow; J Geddes; P Rieckmann; H Tremlett
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

6.  Tobacco mosaic virus delivery of mitoxantrone for cancer therapy.

Authors:  Richard D Lin; Nicole F Steinmetz
Journal:  Nanoscale       Date:  2018-08-30       Impact factor: 7.790

Review 7.  Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.

Authors:  Erik Hefti; Javier G Blanco
Journal:  Cardiovasc Toxicol       Date:  2016-01       Impact factor: 3.231

8.  Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Authors:  C L Hirst; A Pace; T P Pickersgill; R Jones; B N McLean; J P Zajicek; N J Scolding; N P Robertson
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

Review 9.  Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors:  Adnan M Subei; Daniel Ontaneda
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

10.  Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?

Authors:  Anja Mähler; Silvia Mandel; Mario Lorenz; Urs Ruegg; Erich E Wanker; Michael Boschmann; Friedemann Paul
Journal:  EPMA J       Date:  2013-02-18       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.